I reckon whether it is the real deal or not is determined by the clinical trials.
I suspect that many of the people at OARSI have their own agendas and their own drum to beat.
The fact that we only got a 10 minute time slot (that's right, Mozz?) says to me that this event isn't necessarily about putting a spotlight on the most promising trials and treatments. How do you justify giving only 10 minutes to this potential blockbuster?
OARSI is fine, but FDA and TGA decisions are what counts. I can't see any scenario where we get a red light.
OARSI 2024, page-63
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
-0.005(1.92%) |
Mkt cap ! $89.19M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 27.0¢ | 25.5¢ | $261.4K | 990.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9999 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 9445 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |